Raymond James Financial Services Advisors, Inc. Clovis Oncology, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $621,439 - $1.05 Million	-21,159 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$42.06 - $62.4 $34,236 - $50,793	814 Added 4.0%	21,159 $962,000
Q1 2018 Apr 16, 2018	SELL	$50.12 - $67.72 $61,146 - $82,618	-1,220 Reduced 5.66%	20,345 $1.07 Million
Q4 2017 Feb 09, 2018	BUY	$57.69 - $84.58 $524,979 - $769,678	9,100 Added 73.0%	21,565 $1.47 Million
Q3 2017 Oct 26, 2017	BUY	$67.17 - $84.81 $365,404 - $461,366	5,440 Added 77.44%	12,465 $1.03 Million
Q2 2017 Aug 15, 2017	BUY	N/A	7,025	7,025 $658,000

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account